Merck, Eisai detail Keytruda and Lenvima’s endometrial cancer win in confirmatory study
Merck and Eisai were eager to tout a headline phase 3 win in December for their combination therapy of Keytruda and Lenvima because it involves the regimen’s first FDA-approved indication in endometrial cancer. Now we know how big that win is. Keytruda and Lenvima cut the risk of death by 38% over physician’s choice of… Read More »